Global Cannabis Regulatory Summit White Paper 2026

The Global Cannabis Regulatory Summit (GCRS) returned for its second edition in London in 2026, following the inaugural summit on Capitol Hill in Washington, DC, in March 2025. Participants from nearly 30 countries and 20 regulatory jurisdictions met to work through the governance frameworks, scientific standards, operational safeguards and coordination that credible cannabis oversight requires. This white paper collects the papers drawn from those sessions, with a foreword from Will Muecke and E. Stanton McLean of Artemis Growth Partners and Saphira Galoob of the United States Cannabis Roundtable. Three connected pillars run through the report: agreed technical standards, market responsibility, and a pathway to global regulatory alignment for cannabis medicines. It sets out the organisations advancing each one: the Cannabis Medicines Regulatory Accord (CMRA) on regulatory alignment, ASTM International's Committee D37 and the S3 Collective on standards, and the Global Cannabis Responsibility Alliance on accountability. The chapters cover the GCRS standards and responsibility workshops, a regulators' private session led by CANNRA, a global advocacy panel, one year of policy change in Germany, France, Thailand and the United States (with Prohibition Partners' Stephen Murphy on the panel), a keynote from Canadian Senator Tony Dean on legalisation in Canada, the shift from patient access to patient care, implementation lessons from Switzerland, Jamaica, the US and Canada, and medical cannabis trade policy. A closing section, written after the summit, examines US rescheduling to Schedule III and its effects in the US and in Europe. The conclusion is practical: the legal basis for medical cannabis already exists, and the next phase is implementation. The white paper ends with funding proposals for the S3 Collective, the Global Cannabis Responsibility Alliance and the CMRA, and looks ahead to the 2027 summit in Zurich, Switzerland, from 5 to 7 April 2027.

• · Foreword: Global Cannabis Regulatory Summit 2026, London, UK
• · Building Trust Across Global Cannabis Markets
• · GCRS Responsibility Workshops
• · Tension by Design
• · From Patchwork to Pathway
• · Regulators Private Session
• · Global Advocacy Panel
• · Global Cannabis Regulatory Frameworks
• · Keynote Address
• · Advancing Cannabis Medicines
• · Designing Stable Cannabis Regulatory Systems
• · Medical Cannabis and International Trade Policy
• · Medical Cannabis Rescheduling
• Investing in the Infrastructure for Global Standards, Responsibility, and Regulatory Alignment
• · S3 Collective Funding Proposal
• · Global Cannabis Responsibility Alliance
• · Cannabis Medicines Regulatory Accord Funding Proposal

• · Alignment, not treaty reform, is the next step. The UN conventions already permit medical and scientific use; what countries lack is a coherent regulatory framework and the know-how to build one, which is the gap the CMRA is designed to fill.
• · Access is not care. Many systems let patients obtain products but not the clinical guidance to use them safely; physician education, product standards and evidence frameworks that accept observational data are the missing pieces.
• · Responsibility infrastructure has to grow with the market. Where it lags, regulatory gaps fill with irresponsible actors and governments answer with broad restrictions that cut patient access and feed illicit supply.
• · Collect data before the market opens. Once licence revenue funds the measurement, the baseline is gone; Germany's BfArM survey of about 25,000 prescriber datasets shows how even imperfect data can keep reimbursement in place.
• · Regulators need permission to revise. Jamaica spent four years rewriting its 2017 regulations through stakeholder consultation, while most jurisdictions still treat their first rule set as final.
• · Credibility is the new competitive edge in trade. Countries now compete on pharmaceutical-grade quality systems, traceability and regulatory consistency as much as on cultivation capacity.